Pay-For-Delay Deals May Become Rare After Supreme Court Okays FTC Complaint

Supreme Court rules FTC can make its case in court that Solvay’s reverse payment settlement with Actavis and two other generic companies was anticompetitive; GPhA says opinion could decrease the number of patent challenges by generic manufacturers.